How to Obtain a Drug Manufacturing License in China: 2026 Guide
A Drug Manufacturing License (药品生产许可证, Drug Manufacturing License, yàopǐn shēngchǎn xǔkězhèng) is a mandatory regulatory approval issued by China’s National Medical Products Administration (NMPA, 国家药品监督管理局, Guójiā Yàopǐn Jiāndū Guǎnlǐ Jú). In 2026, executing this process requires navigating three distinct stages — pre-qualification, on-site GMP inspection, and final certification — which together demand an average of 100–140 working days to complete from application submission to license issuance.
Understanding the Regulatory Framework in 2026
China’s pharmaceutical regulatory environment has tightened considerably since the 2023 NMPA reforms. The Drug Manufacturing License is now governed jointly by the NMPA and provincial Medical Products Administrations (MPA), with risk-based classification determining oversight intensity. The system processes approximately 1,200 new license applications annually across China, with the top five provinces — Jiangsu, Shandong, Guangdong, Zhejiang, and Beijing — accounting for 62% of all approved licenses (source: NMPA Annual Report 2025).
The license itself is valid for five years, subject to annual GMP compliance reports and a full renewal audit in the fourth year. Failure to renew on time results in automatic suspension of manufacturing operations, with reinstatement requiring a full re-application cycle costing an estimated RMB 150,000–300,000 in administrative and consultant fees plus 80–120 working days of lost production time.
| License Category | Product Scope | GMP Inspection Type | Typical Processing Time (Working Days) | Application Fee (RMB) |
|---|---|---|---|---|
| Class A — Chemical Drugs | APIs, intermediates, finished chemical dosage forms | Full on-site + lab audit | 100–130 | 2,500 |
| Class B — Biological Products | Vaccines, blood products, recombinant therapeutics | Enhanced on-site + continuous monitoring | 120–160 | 5,000 |
| Class C — Traditional Chinese Medicine | Decoctions, patent TCM formulas, extracts | Standard on-site + material traceability check | 80–110 | 2,000 |
| Class D — APIs for Export Only | Active pharmaceutical ingredients not for domestic sale | Document review + reduced on-site | 60–90 | 1,500 |
Source: NMPA Fee Schedule (valid through December 2026) and provincial MPA processing benchmarks.
Eligibility Requirements for Foreign Investors
Foreign companies entering China’s drug manufacturing space must establish a Wholly Foreign-Owned Enterprise (外商独资企业, WFOE, wàishāng dúzī qǐyè) or a Joint Venture (合资企业, Joint Venture, hézī qǐyè) in a permitted industrial zone. The 2025 Negative List removed restrictions on foreign ownership for chemical drug and API manufacturing, but biological products — especially vaccines and blood derivatives — remain in restricted categories requiring a Chinese partner holding at least 50% equity.
Key eligibility documentation includes a valid business license for the China entity (minimum registered capital of RMB 10 million for Class A, RMB 20 million for Class B), proof of GMP-compatible facilities (either owned or under long-term lease of 5+ years), and a quality management system certificate (ISO 13485 or equivalent) for Class B applicants. The NMPA reported in Q1 2026 that 31% of foreign-led applications failed at the eligibility review stage, primarily due to insufficient capital verification or unapproved facility locations in non-pharmaceutical industrial parks.
Step-by-Step Application Process
Stage 1: Pre-Submission (4–8 Weeks)
Begin by engaging a China-based regulatory affairs consultant with NMPA experience. Submit a Pre-Application Consultation Request (预申请咨询, Pre-Application Consultation, yù shēnqǐng zīxún) to the provincial MPA — this step is not mandatory but reduces application rejection risk by approximately 40% (NMPA advisory, 2025). Prepare a Master File containing facility blueprints, equipment lists, production flow diagrams, and environmental impact assessment reports.
Stage 2: Formal Application Submission (Day 1–30)
File the application through the NMPA Online Service Platform (https://zwfw.nmpa.gov.cn) using your company’s Unified Social Credit Code. Attach all required documents in both Chinese and English versions. Pay the application fee online — RMB 2,500 for Class A, RMB 5,000 for Class B. The provincial MPA has 5 working days to conduct a formal completeness review. In 2025, 22% of applications were returned at this stage for missing or incorrect documentation, adding 15–25 working days to the timeline.
Stage 3: Technical Review and GMP Inspection (30–90 Days)
NMPA-appointed inspectors will conduct a document-based technical review (technical review, shěnchá) lasting 20–40 working days. If approved at this stage, an on-site GMP inspection (现场检查, on-site inspection, xiànchǎng jiǎnchá) is scheduled within 15 working days. GMP inspection typically lasts 3–5 days for Class A, 5–7 days for Class B, and covers six core modules: premises and equipment, personnel and training, production management, quality control, documentation, and product testing. Since the 2024 GMP update, inspectors now require live demonstration of three consecutive validation batches for your lead product.
Stage 4: License Issuance (10–20 Days)
After a successful GMP inspection, the inspection team submits a report to the NMPA Licensing Committee. The Committee votes on approval within 10 working days. Approved applications receive a digital license (电子许可证, electronic license, diànzǐ xǔkězhèng) via the online platform. Physical licenses are mailed within 5 business days. The final license includes a unique 12-digit code, manufacturing scope, and designated product categories.
Decision Framework: Choose Your Application Path
If your primary product is an active pharmaceutical ingredient (API) for export only and you do not plan to sell into China’s domestic market, choose Class D — this category requires the shortest processing time (60–90 working days) and the lowest application fee (RMB 1,500), with reduced on-site inspection scope. If you are manufacturing finished chemical drugs (tablets, injections, capsules) for the Chinese domestic market, choose Class A — it balances processing speed (100–130 days) with full domestic market access. If your product is a biological drug — vaccine, monoclonal antibody, or blood derivative — choose Class B, but prepare for enhanced GMP inspections and a Chinese joint venture partner if the product falls under restricted categories.
Post-Approval Compliance and Market Access
Your Drug Manufacturing License is the gateway to distributing products in China. For domestic sales, you must additionally obtain a Drug Registration Certificate (药品注册证书, Drug Registration Certificate, yàopǐn zhùcè zhèngshū) for each product — this is a separate process under NMPA requiring clinical trial data (for new drugs) or bioequivalence studies (for generics). For export-only manufacturers (Class D), no domestic registration is needed, but products must comply with the importing country’s standards, and NMPA export certification is available upon request.
As of 2026, China’s pharmaceutical market is valued at approximately RMB 2.5 trillion (USD 345 billion) with an annual growth rate of 6.8% (IQVIA China Report 2026). Foreign-invested manufacturers hold 22% of domestic market share, concentrated in innovative drugs (38% of market share) and patented biologics (45% of market share). New entrants with NMPA-approved facilities typically reach first commercial revenue within 12–18 months of license issuance.
NEXT STEPS
- Pre-submit a consultation request to your provincial MPA to identify potential eligibility gaps before you invest significant resources. Read our detailed guide: NMPA Pre-Application Consultation: Step-by-Step Walkthrough.
- Engage a local regulatory affairs partner with proven NMPA GMP inspection track record. Compare vetted consultants in our directory: Top 10 China Drug Manufacturing Regulatory Consultants (2026).
- Validate your facility location against the current list of NMPA-Designated Pharmaceutical Industrial Parks. Download the updated provincial lists: 2026 China Pharmaceutical Industrial Park Directory (Searchable Database).
— China Gateway 360 —
Remote China market entry support, built around execution.
